← Back to Search

Intraarterial Carboplatin Combinations for Glioblastoma

Sherbrooke, Canada
Phase 2
Recruiting
Led By David Fortin, MD
Research Sponsored by Université de Sherbrooke
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up when death is reported; through study completion, an average of 2 years
Awards & highlights
No Placebo-Only Group

Summary

"This trial is testing a new treatment approach for glioblastoma, a type of brain cancer. The current standard treatment involves surgery, radiation, and chemotherapy, but relapse is common. This trial

See full description
Who is the study for?
This trial is for individuals with glioblastoma that has recurred or is relapsing. Participants must have already undergone standard treatment including surgery, radiotherapy, and temozolomide. They should be eligible for additional surgery if needed and able to receive intraarterial chemotherapy.
What is being tested?
The study tests two combinations of intraarterial chemotherapy: Carboplatin with Caelyx versus Carboplatin with Etoposide Phosphate in patients whose glioblastoma has progressed after initial treatment. The goal is to improve progression-free survival (PFS) and overall survival (OS).See study design
What are the potential side effects?
Potential side effects include those common to chemotherapy such as nausea, fatigue, hair loss, increased risk of infection due to lowered blood counts, potential kidney or liver damage, and possible allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~when death is reported; through study completion, an average of 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and when death is reported; through study completion, an average of 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression-free Survival
Tumor Response on MRI using the RANO Criteria
Secondary study objectives
Incidence of treatment related Neurocognitive decline
Median overall survival
Per treatment quality of life assessment
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: IA Carboplatin + IA Etoposide PhosphateExperimental Treatment1 Intervention
Participants will be treated with IA carboplatin + IA etoposide phosphate on each cycle (4-6 weeks), for up to 12 cycles.
Group II: IA Carboplatin + IA CaelyxExperimental Treatment1 Intervention
Participants will be treated with IA carboplatin + IA liposomal doxorubicin on each cycle (4-6 weeks), for up to 12 cycles.

Find a Location

Closest Location:CHUS· Sherbrooke, Canada· 681 miles

Who is running the clinical trial?

Université de SherbrookeLead Sponsor
316 Previous Clinical Trials
79,410 Total Patients Enrolled
1 Trials studying Glioblastoma
35 Patients Enrolled for Glioblastoma
David Fortin, MDPrincipal InvestigatorEstrie University Integrated Health and Social Services Center - University Hospital of Sherbrooke
1 Previous Clinical Trials
35 Total Patients Enrolled
1 Trials studying Glioblastoma
35 Patients Enrolled for Glioblastoma
~80 spots leftby Apr 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top